WO2007051007A3 - Combination of antihypertensives with cholesterol-lowering agent - Google Patents

Combination of antihypertensives with cholesterol-lowering agent Download PDF

Info

Publication number
WO2007051007A3
WO2007051007A3 PCT/US2006/042305 US2006042305W WO2007051007A3 WO 2007051007 A3 WO2007051007 A3 WO 2007051007A3 US 2006042305 W US2006042305 W US 2006042305W WO 2007051007 A3 WO2007051007 A3 WO 2007051007A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol
lowering agent
antihypertensives
combination
product
Prior art date
Application number
PCT/US2006/042305
Other languages
French (fr)
Other versions
WO2007051007A2 (en
Inventor
Randy Lee Webb
Suraj Shivappa Shetty
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Randy Lee Webb
Suraj Shivappa Shetty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Randy Lee Webb, Suraj Shivappa Shetty filed Critical Novartis Ag
Publication of WO2007051007A2 publication Critical patent/WO2007051007A2/en
Publication of WO2007051007A3 publication Critical patent/WO2007051007A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a product comprising at least two antihypertensive agents and a cholesterol-lowering agent wherein at least one of the antihypertensive agents is a neutral endopeptidase inhibitor, and the other antihypertensive agent is typically but not necessarily an angiotensin II receptor antagonist. The invention further relates to the use of said product in treatment of relevant conditions, or diseases, or disorders such as cardiovascular conditions.
PCT/US2006/042305 2005-10-28 2006-10-27 Combination of antihypertensives with cholesterol-lowering agent WO2007051007A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73145105P 2005-10-28 2005-10-28
US60/731,451 2005-10-28

Publications (2)

Publication Number Publication Date
WO2007051007A2 WO2007051007A2 (en) 2007-05-03
WO2007051007A3 true WO2007051007A3 (en) 2007-09-13

Family

ID=37968615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/042305 WO2007051007A2 (en) 2005-10-28 2006-10-27 Combination of antihypertensives with cholesterol-lowering agent

Country Status (1)

Country Link
WO (1) WO2007051007A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075344A1 (en) 2009-01-30 2011-03-23 Takeda Pharmaceutical FITTED NITROGEN HETEROCICLIC DERIVATIVES, MEDICINES CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF CARDIAC, RENAL AND METABOLIC DISEASES, AMONG OTHER
CN106177960B (en) * 2016-08-01 2019-01-08 珠海赛隆药业股份有限公司（长沙）医药研发中心 Angiotensin receptor antagonist and the compound of enkephalinase inhibitor and application thereof
EP3881840A1 (en) * 2020-03-19 2021-09-22 Insusense ApS Sortilin antagonists for use inthe treatment of diabetic retinopathy

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0498361A2 (en) * 1991-02-06 1992-08-12 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
EP1314425A1 (en) * 2000-08-30 2003-05-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
WO2003059345A1 (en) * 2002-01-17 2003-07-24 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
US20040132731A1 (en) * 2002-06-26 2004-07-08 Fox David Nathan Abraham Novel combination
WO2004062729A1 (en) * 2003-01-16 2004-07-29 Boehringer Ingelheim International Gmbh Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
WO2004062557A2 (en) * 2003-01-16 2004-07-29 Boehringer Ingelheim International Gmbh Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
WO2004082636A2 (en) * 2003-03-18 2004-09-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor
WO2005030215A2 (en) * 2003-09-26 2005-04-07 Astrazeneca Uk Limited Therapeutic treatment
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2006086456A2 (en) * 2005-02-11 2006-08-17 Novartis Ag Combination of organic compounds

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0498361A2 (en) * 1991-02-06 1992-08-12 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
EP1314425A1 (en) * 2000-08-30 2003-05-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
WO2003059345A1 (en) * 2002-01-17 2003-07-24 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
US20040132731A1 (en) * 2002-06-26 2004-07-08 Fox David Nathan Abraham Novel combination
WO2004062729A1 (en) * 2003-01-16 2004-07-29 Boehringer Ingelheim International Gmbh Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
WO2004062557A2 (en) * 2003-01-16 2004-07-29 Boehringer Ingelheim International Gmbh Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
WO2004082636A2 (en) * 2003-03-18 2004-09-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor
WO2005030215A2 (en) * 2003-09-26 2005-04-07 Astrazeneca Uk Limited Therapeutic treatment
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2006086456A2 (en) * 2005-02-11 2006-08-17 Novartis Ag Combination of organic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HERMIDA R ET AL: "Administration time-dependent effects of low-dose aspirin on ambulatory blood pressure in untreated hypertensive patients", ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER, vol. 5, no. 1, April 2004 (2004-04-01), pages 122, XP004868724, ISSN: 1567-5688 *

Also Published As

Publication number Publication date
WO2007051007A2 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
WO2008011392A3 (en) Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2008033562A3 (en) Kinase inhibitor compounds
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
WO2007112288A3 (en) Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2008073933A3 (en) 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
WO2007022518A3 (en) New uses of glucoregulatory proteins
WO2005117858A3 (en) Compositions comprising nebivolol
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
WO2007024949A3 (en) Alpha2c adrenoreceptor agonists
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2006015159A3 (en) Potassium channel inhibitors
WO2009042114A3 (en) Phenazine derivatives and uses thereof
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2010068710A3 (en) Kinase inhibitor compounds
WO2006128143A3 (en) Hydantoin compounds
WO2009017863A3 (en) Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
WO2007125105A3 (en) Benzamide glucokinase activators
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2008036379A3 (en) Serine hydrolase inhibitors
WO2006130174A3 (en) Compositions comrising nebivolol

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06836654

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06836654

Country of ref document: EP

Kind code of ref document: A2